Myriad Genetics Inc.
09/04/2024 | Press release | Distributed by Public on 09/04/2024 04:03
Regulation FD Disclosure Form 8 K
ITEM 7.01 Regulation FD Disclosure.
Myriad Genetics, Inc. (the "Company") previously reported the initial results of a retrospective, multi-part, economic utility study linking patients who had received GeneSight testing to administrative insurance claims from a nationwide data warehouse in the United States. The Company partnered with a leading third-party vendor to conduct the multi-part study.
As initially reported in April 2024, the results of part one of the study, the full results of which the Company plans to publish in the near future, showed that, in the first 180 days after GeneSight testing, the percentage of patients with hospitalizations for any reason and psychiatric-related hospitalizations decreased by 29% and 39%, respectively. Based on prior GeneSight studies, the Company hypothesized that GeneSight testing had contributed to the reduction in hospitalizations. Part one of the study, however, did not include a non-GeneSight control group to evaluate whether or to what extent GeneSight testing was the cause of the reduction in hospitalizations. The Company planned to conduct an additional analysis of the administrative insurance claims data with a non-GeneSight control group with the goal to test the Company's hypothesis and share the results of this second part of the study in the second half of 2024.
Part two of this study was designed to analyze the hospital resource utilization and costs of a group of patients who had received GeneSight testing compared to a matched control group of patients who had not received GeneSight testing. To identify the non-GeneSight control group, the Company directed the third-party vendor to review its data warehouse to identify a group of patients that best matched the characteristics of the GeneSight patient group. After the best-matched non-GeneSight control group was identified using the available data, the Company identified significant disparities between the GeneSight patient group and this non-GeneSight control group in baseline hospital resource utilization and costs. The Company believes such disparities indicated that this non-GeneSight control group was not a viable control for part two of the study. As a result, the Company concluded that any data comparing the GeneSight patient group against this non-GeneSight control group were not reliable. Therefore, the Company has determined to discontinue the analysis for this part of the study.